Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.810
+0.350 (10.12%)
At close: Aug 13, 2025, 4:00 PM
3.650
-0.160 (-4.20%)
Pre-market: Aug 14, 2025, 9:12 AM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Prime Medicine stock ranges from a low of $1.50 to a high of $18. The average analyst price target of $8.88 forecasts a 133.07% increase in the stock price over the next year.
Price Target: $8.88 (+133.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +162.47% | Aug 8, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $10 → $1.5 | Strong Buy → Hold | Downgrades | $10 → $1.5 | -60.63% | May 27, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +57.48% | May 20, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 20, 2025 |
Financial Forecast
Revenue This Year
6.77M
from 2.98M
Increased by 126.92%
Revenue Next Year
12.68M
from 6.77M
Increased by 87.32%
EPS This Year
-1.32
from -1.65
EPS Next Year
-1.03
from -1.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 84.0M | 141.8M | ||
| Avg | 6.8M | 12.7M | 30.5M | ||
| Low | 1.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 533.6% | 1,141.0% | 1,017.9% | ||
| Avg | 126.9% | 87.3% | 140.8% | ||
| Low | -52.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.80 | -0.48 | ||
| Avg | -1.32 | -1.03 | -0.95 | ||
| Low | -1.57 | -1.57 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.